AbCellera is a Canadian biotechnology company headquartered in Vancouver, built around a proprietary antibody discovery platform that it licenses to pharmaceutical and biotech partners developing new drug candidates. Listed on Nasdaq under the ticker ABCL.O, the company gained widespread recognition during the COVID-19 pandemic as the discoverer of bamlanivimab, an antibody treatment developed in partnership with Eli Lilly and Company, which brought both revenue and visibility to a business that had previously operated largely below mainstream investor radar.
The underlying business model is distinctive: rather than advancing drugs through the full clinical pipeline itself, AbCellera acts as an upstream discovery partner, taking royalties and milestones as its partners progress candidates towards commercialisation. That royalty-driven structure gives the company long-term revenue potential largely decoupled from the operational complexity of running clinical trials, though near-term income can be lumpy and heavily dependent on partner development timelines.
Please note this is marketing communication, not recommendation or advice.
comptes clients
FxPro fournit des services de trading en ligne à ses clients depuis 1999 et est actuellement présent dans 173 pays.
Prix
FxPro est régulièrement reconnu dans le secteur et a remporté plus de 145 récompenses internationales jusqu'à aujourd'hui pour la qualité de ses services.
service client
Notre équipe de service client multilingue et dévouée travaille 24h/24 et 5j/7 pour vous fournir une assistance exceptionnelle.
réglementations sectorielles
FxPro opère sous une stricte surveillance réglementaire dans plusieurs juridictions, y compris l'autorisation de la FCA au Royaume-Uni - l'un des régulateurs financiers les plus fiables au monde.
